X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (2) 2
12 (1) 1
23 (1) 1
bevacizumab (1) 1
breast (1) 1
digestive system diseases (1) 1
double-blind (1) 1
fda (1) 1
hepatocellular carcinoma (1) 1
phase-3 trial (1) 1
placebo (1) 1
regorafenib (1) 1
regulatory issues (1) 1
regulatory issues: fda (1) 1
sorafenib (1) 1
trial (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 04/2018, Volume 23, Issue 4, pp. 496 - 500
Regorafenib is the first drug approved by the FDA for the treatment of hepatocellular carcinoma that has progressed on sorafenib and is expected to become a... 
Regorafenib | Hepatocellular carcinoma | Sorafenib | PLACEBO | ONCOLOGY | PHASE-3 TRIAL | DOUBLE-BLIND | 12 | 23 | FDA | Regulatory Issues
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2018, Volume 24, Issue 17, pp. 4066 - 4071
The FDA approved niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial... 
TRIAL | ONCOLOGY | BEVACIZUMAB | BREAST
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.